EZH2 and hepatocellular carcinoma: Chromatin modifiers, in particular the polycomb-repressive complexes 2 subunit IEnhancer of zeste homolog 2 (EZH2), have been reported in many studies to be overexpressed in HCC samples and this is often associated with poor prognosis in liver cancer patients [16-18].